ALK closes largest deal in 10 years – gets DKK 90m for partnership in China on adrenaline autoinjector
Allergy firm ALK has entered a collaboration with Chinese company Grandpharma, which pays DKK 90m for the right to sell ALK's adrenaline autoinjector Jext in China. ALK further gains earnings from the sales, and ALK CEO Carsten Hellmann predicts this will be visible on both the company's top and bottom line many years from now.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
On Friday, Denmark-based allergy company ALK announced it had entered a partnership with Chinese company Grandpharma to distribute and sell ALK's adrenaline pen Jext in the populous country over the next 16 years.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish companies: A minimum tax rate has advantages
For subscribers
